NASDAQ:ATOS Atossa Genetics Q3 2026 Earnings Date & Estimates $2.56 +0.17 (+7.11%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$2.50 -0.06 (-2.34%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Atossa Genetics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 12, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Atossa Genetics in Q3 2026Atossa Genetics is expected to post earnings of -$0.86 per share. In the same quarter a year earlier Atossa Genetics reported -$1.05 per share. Atossa Genetics last reported on August 7, 2026, posting -$0.95 per share and beating the -$1.02 consensus estimate. Atossa Genetics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.86Prior-Year EPS-$1.05Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.95 (Beat by +$0.07)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Atossa Genetics Q3 2026 Earnings FAQ When does Atossa Genetics report Q3 2026 earnings? Atossa Genetics (NASDAQ:ATOS) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Atossa Genetics' Q3 2026 earnings call? Atossa Genetics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Atossa Genetics? Analysts expect Atossa Genetics to post earnings of -$0.86 per share for Q3 2026. Atossa Genetics Earnings HeadlinesAtossa (NASDAQ: ATOS) ties PRV payout to 25% of voucher proceeds under CVR dealOctober 12 at 3:02 AM | americanbankingnews.comAtossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValueOctober 9, 2026 | prnewswire.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on. | Behind the Markets (Ad)Q3 EPS Forecast for Atossa Genetics Raised by AnalystOctober 6, 2026 | americanbankingnews.comAtossa plans shareholder stake in potential PRV proceedsSeptember 30, 2026 | msn.comAtossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherSeptember 29, 2026 | prnewswire.comSee More Atossa Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atossa Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atossa Genetics and other key companies, straight to your email. Email Address About Atossa GeneticsAtossa Genetics (NASDAQ:ATOS), Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. The company’s research is centered on precision medicines intended to address unmet needs in breast cancer treatment and prevention. Atossa’s leading development program is oral endoxifen, an active metabolite of tamoxifen and a selective estrogen receptor modulator. The company is evaluating endoxifen in clinical studies involving hormone receptor-positive breast cancer, including settings before surgery and in patients who may benefit from reducing tumor activity or breast cancer risk. Founded in 2009 and headquartered in Seattle, Washington, Atossa initially pursued diagnostic products for breast health before concentrating its business on therapeutic development. The company serves the global biopharmaceutical and medical research markets through its clinical programs and collaborations. Steven Quay, M.D., Ph.D., is the company’s founder and chief executive officer.View Atossa Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
